Temperature dependence of site-resolved Fe magnetic moments in ThMn12-type Sm(Fe1−xCox)12 compounds studied via synchrotron Mössbauer spectroscopy

The relationship between the magnetization and magnetic moment at each Fe site in Sm(Fe 1− x Co x ) 12 compounds and their temperature dependence were investigated via synchrotron Mössbauer spectroscopy. The enhancement in the Fe magnetic moments in the Sm(Fe 1− x Co x ) 12 compounds with increasing Co content was observed at a similar rate as the increment in their saturation magnetization at 300 K. We found that the magnitudes of the Fe magnetic moments vary in a descending order: 8i > 8j > 8f, and they are independent of the Co content because the variation is caused by the magneto-volume effect. The curvatures of the temperature dependence of the Fe-sublattice magnetic moments are larger and also vary in the order of 8i > 8j > 8f because the enhancements in the exchange couplingstrength decrease in the same order

Glucagon-like peptide-1 receptor agonists as an effective therapeutic agent for diabetes mellitus and obesity in patients with schizophrenia under treatment with second-generation antipsychotics

Objectives: Cases of schizophrenia are commonly complicated with obesity and diabetes mellitus partially caused by excessive eating associated with the use of second-generation antipsychotics (SGAs). We aimed to study the efficacy of glucagon-like peptide-1 in patients with schizophrenia under treatment with SGAs. Methods: Diabetic patients with schizophrenia were included if their HbA1c levels increased more than 1% and/or their weight increased more than 3 kg after treatment with SGAs. Patients who developed diabetes after treatment with SGAs were also included. The participants were treated with GLP-1 receptor agonists for one year, and their changes in weight and HbA1c and any adverse events were evaluated. Results: Seven patients were treated with GLP-1 receptor agonists; their mean age was 46.1 yrs old (range; 26 to 59), mean body weight was 85.3 kg (65.5 to 96.8), and mean BMI was 33.8 (27 to 38.7). Five of them showed improvement in their HbA1c levels of 1.2% (0.1 to 3.4, p=0.089) with a weight loss of 3.7 kg (-9.6 to +3.5, p=0.14) on average. The adverse effects observed were all gastrointestinal, but were not severe enough to cause termination of the GLP-1 receptor agonist treatment. The GLP-1 receptor agonist was not effective in one patient, and another patient terminated the treatment in a few months. Conclusions: Although the number of patients studied was small, GLP-1 receptor agonists seem to be effective for treating diabetes and bringing about weight loss in patients with schizophrenia under treatment with SGAs